Advaxis, Inc. And University of California, San Francisco (UCSF) To Evaluate Cancer Immunotherapy Constructs In Prostate Cancer

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PRINCETON, N.J., March 17, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it has signed an agreement with the University of California, San Francisco (UCSF), under which Lawrence Fong, M.D., Professor in the Department of Medicine and principal investigator of the studies at UCSF, will evaluate several new immunotherapy constructs, in addition to ADXS-PSA, each built on the Advaxis proprietary technology. Data generated from this agreement will demonstrate the combination of the unique Advaxis immunotherapy platform, which generates both tumor fighting T cells and reduces tumor protection inside the tumor microenvironment, with targets that have already been shown to be important in effective immunotherapies for prostate cancer.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC